Nasdaq

Solid Biosciences Reports Promising Initial Data from Phase 1/2 INSPIRE DUCHENNE Trial for SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences has reported promising initial findings from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first three ...
Seeking Alpha

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with ...
Business Insider

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex ...
Nasdaq

Solid Biosciences Inc. to Present Phase 1/2 INSPIRE DUCHENNE Trial Data on SGT-003 Gene Therapy for Duchenne Muscular Dystrophy at 2025 MDA Conference

Solid Biosciences will present Phase 1/2 trial data for SGT-003 gene therapy targeting Duchenne muscular dystrophy at MDA Conference. Solid Biosciences Inc. will present data from its Phase 1/2 ...
Seeking Alpha

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

- Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle integrity, including stabilization and ...